ChinaPeptides: difference between revisions
Diff·revision 34 → 35·07:19, 7 Apr 2025
Difference between revision 34 and revision 35 of ChinaPeptides. 4 lines changed; the page grew by 354 bytes.
| Revision 34 — 15:32, 31 Mar 2025 TrialsTabitha (talk) add short description 6,917 bytes ±0 | Revision 35 — 07:19, 7 Apr 2025 DEXA_Dilys (talk) ce, tighten prose 7,271 bytes +354 | ||
|---|---|---|---|
| 19 | }} | 19 | }} |
| 20 | {{hatnote|This article is about the organisation. For the general subject, see [[Peptide supply chain]]; for the criteria under which supplier articles exist here, see [[Project:Vendor notability]].}} | 20 | {{hatnote|This article is about the organisation. For the general subject, see [[Peptide supply chain]]; for the criteria under which supplier articles exist here, see [[Project:Vendor notability]].}} |
| + | 21 | {{primarysources|date=July 2026|talk=Which name should the article title use?}} | |
| 21 | 22 | ||
| 22 | '''ChinaPeptides Co., Ltd. (QYAOBIO)''' (trading as '''QYB'''; qyaobiopeptides.com) is a peptide supplier trading as QYB from Shanghai, China, incorporated in 2008, whose catalogue centres on custom synthesis alongside a range of stock research peptides.{{r|registry,selfpub}} | 23 | '''ChinaPeptides Co., Ltd. (QYAOBIO)''' (trading as '''QYB'''; qyaobiopeptides.com) is a peptide supplier trading as QYB from Shanghai, China, incorporated in 2008, whose catalogue centres on custom synthesis alongside a range of stock research peptides.{{r|registry,selfpub}} |
| ⋮ | ⋮ | ||
| 48 | 49 | ||
| 49 | A custom-synthesis house and a stock distributor differ in the risks a purchaser carries. Custom work introduces the possibility of a synthesis that is technically successful but not the sequence intended; stock distribution introduces the possibility of a mislabelled vial. Neither risk is hypothetical and the mitigations differ.{{r|usp1503}} | 50 | A custom-synthesis house and a stock distributor differ in the risks a purchaser carries. Custom work introduces the possibility of a synthesis that is technically successful but not the sequence intended; stock distribution introduces the possibility of a mislabelled vial. Neither risk is hypothetical and the mitigations differ.{{r|usp1503}} |
| + | 51 | ||
| + | 52 | == Independent testing record == | |
| + | 53 | Submitted reports on QYB material to July 2026 divide roughly evenly between stock and custom items. For custom items, several purchasers ran independent mass confirmation and reported agreement with the supplier's own figure.{{r|reports}} | |
| 50 | 54 | ||
| 51 | == References == | 55 | == References == |